Scienture Secures REZENOPY Patent Until 2041
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 14 2026
0mins
Should l Buy SCNX?
Scienture announced that the United States Patent and Trademark Office, USPTO, has issued U.S. Patent No. 12,514,854 B2, an Orange Book-listable patent covering REZENOPY Nasal Spray 10 mg, effective January 6, 2026, with an expiry date of February 5, 2041. The patent was issued to Summit Biosciences, a subsidiary of Kindeva Drug Delivery L.P. As previously disclosed, Scienture, a wholly owned subsidiary of Scienture Holdings, entered into a definitive agreement with Summit in March 2025 for the exclusive U.S. commercialization rights to REZENOPY. Under the terms of the collaboration, Summit will manufacture and commercially supply REZENOPY. Pending certain commercial obligations, Scienture will own the new drug application, NDA, for REZENOPY in its name and be responsible for the sales, marketing and distribution of the product in the U.S. through Scienture's commercial operations infrastructure.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SCNX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SCNX
About SCNX
Scienture Holdings, Inc., through its wholly owned subsidiary, Scienture, LLC, is a specialty pharmaceutical company focused on providing enhanced value to patients, physicians and caregivers by offering specialty products to satisfy unmet market needs. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The Company's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Scienture Holdings Reports Transformational 2025 Financial Results with Significant Revenue Growth
- Significant Revenue Growth: Scienture's net revenue for 2025 reached $431,609, a 216% increase from $136,643 in 2024, primarily driven by the FDA approval and commercial launch of Arbli in Q3, marking a successful transformation in the pharmaceutical market.
- Gross Margin Expansion: The gross margin surged from 4.4% last year to 76.8% in 2025, reflecting a shift towards higher-margin branded pharmaceuticals, enhancing overall profitability and laying a foundation for sustainable future growth.
- Expanded Commercial Network: Through agreements with PBMs and institutional GPOs, Arbli's market access has expanded to over 2,500 U.S. healthcare institutions, securing formulary inclusion with major national health plans covering over 100 million lives, significantly increasing product penetration.
- Positive Future Outlook: Scienture anticipates continued momentum for Arbli in 2026, with plans for the commercial launch of REZENOPY in Q2, further solidifying its competitive position in the U.S. pharmaceutical market.
See More
Scienture Holdings Reports FY Earnings
- Earnings Overview: Scienture Holdings reported FY GAAP EPS of -$2.70, indicating challenges in profitability that may affect investor confidence moving forward.
- Revenue Surge: The company achieved revenue of $0.43M, reflecting a significant year-over-year increase of 207.1%, suggesting notable improvement in market demand despite the overall financial performance needing enhancement.
- Historical Financial Data: The release includes historical earnings data, providing investors with context for the company's performance and aiding in the analysis of long-term trends and potential risks.
- Future Outlook: While the current financial situation is concerning, the substantial revenue growth may present opportunities for strategic adjustments and market expansion, warranting investor attention on future developments.
See More
SCIENTER RELEASES 2025 YEAR-END FINANCIAL RESULTS AND BUSINESS UPDATE
Financial Results Overview: The report outlines the financial performance of the company for the year ending 2025, highlighting key metrics and overall profitability.
Business Update: It provides insights into recent business developments, including strategic initiatives and market positioning.
Future Projections: The report discusses anticipated trends and forecasts for the upcoming years, indicating potential growth areas.
Operational Highlights: Key operational achievements and challenges faced during the year are summarized, showcasing the company's resilience and adaptability.
See More
Scienture Holdings Shares Surge 31% Following GPO Agreements
- Significant Stock Surge: Scienture Holdings, Inc. (SCNX) shares have risen approximately 31% in Wednesday morning trading, currently priced at $0.51, reflecting strong market response despite a slight decline from the opening price of $0.61.
- Impact of Agreements: The company has formalized multiple commercial Group Purchasing Organization agreements for its REZENOPYTM (naloxone HCl) Nasal Spray 10 mg, which is expected to significantly expand its market reach within healthcare institutions.
- Market Penetration Potential: These agreements will provide access to over 5,000 healthcare facilities, representing a potential penetration of approximately 60% of the U.S. institutional market, thereby offering robust support for future sales growth.
- Historical Trading Range: Over the past year, SCNX has traded between $0.37 and $3.17, and the current stock performance indicates a positive market sentiment regarding the company's future prospects.
See More
SCIENTURE STOCK RISES 60.1% IN PREMARKET TRADING FOLLOWING DEALS TO BROADEN DISTRIBUTION OF OPIOID OVERDOSE SPRAY
Market Growth: Shares of Scienture have increased by 60.1% in pre-market trading.
Expansion Plans: The company has signed deals to expand the reach of its opioid overdose spray.
See More
Scienture Launches ARBLI™ and Confirms REZENOPY™ Launch Timeline
- Market Opportunity Expansion: Scienture has significantly enhanced ARBLI™'s coverage in the U.S. market through agreements with multiple pharmacy benefit managers (PBMs), which is expected to drive sales growth in the $241 million losartan market, further solidifying the company's position in hypertension treatment.
- Institutional Collaboration Enhancement: The company has signed agreements with over 2,500 healthcare institutions, ensuring widespread accessibility of ARBLI™, which not only improves patient medication convenience but also lays a solid foundation for future revenue growth.
- Financial Position Improvement: As of December 31, 2025, Scienture reported approximately $7 million in cash reserves and significantly improved its balance sheet by reducing debt, providing ample funding to execute its commercial strategy and support the continued growth of ARBLI™.
- REZENOPY™ Launch Plan: Scienture has confirmed the launch of REZENOPY™ in the second quarter of 2026, marking the company's second naloxone product in the U.S. market, which is expected to leverage the commercial infrastructure established through ARBLI™ to further expand market share.
See More
Scienture Holdings Reports Transformational 2025 Financial Results with Significant Revenue Growth
- Significant Revenue Growth: Scienture's net revenue for 2025 reached $431,609, a 216% increase from $136,643 in 2024, primarily driven by the FDA approval and commercial launch of Arbli in Q3, marking a successful transformation in the pharmaceutical market.
- Gross Margin Expansion: The gross margin surged from 4.4% last year to 76.8% in 2025, reflecting a shift towards higher-margin branded pharmaceuticals, enhancing overall profitability and laying a foundation for sustainable future growth.
- Expanded Commercial Network: Through agreements with PBMs and institutional GPOs, Arbli's market access has expanded to over 2,500 U.S. healthcare institutions, securing formulary inclusion with major national health plans covering over 100 million lives, significantly increasing product penetration.
- Positive Future Outlook: Scienture anticipates continued momentum for Arbli in 2026, with plans for the commercial launch of REZENOPY in Q2, further solidifying its competitive position in the U.S. pharmaceutical market.
See More
Scienture Holdings Reports FY Earnings
- Earnings Overview: Scienture Holdings reported FY GAAP EPS of -$2.70, indicating challenges in profitability that may affect investor confidence moving forward.
- Revenue Surge: The company achieved revenue of $0.43M, reflecting a significant year-over-year increase of 207.1%, suggesting notable improvement in market demand despite the overall financial performance needing enhancement.
- Historical Financial Data: The release includes historical earnings data, providing investors with context for the company's performance and aiding in the analysis of long-term trends and potential risks.
- Future Outlook: While the current financial situation is concerning, the substantial revenue growth may present opportunities for strategic adjustments and market expansion, warranting investor attention on future developments.
See More
SCIENTER RELEASES 2025 YEAR-END FINANCIAL RESULTS AND BUSINESS UPDATE
Financial Results Overview: The report outlines the financial performance of the company for the year ending 2025, highlighting key metrics and overall profitability.
Business Update: It provides insights into recent business developments, including strategic initiatives and market positioning.
Future Projections: The report discusses anticipated trends and forecasts for the upcoming years, indicating potential growth areas.
Operational Highlights: Key operational achievements and challenges faced during the year are summarized, showcasing the company's resilience and adaptability.
See More
Scienture Holdings Shares Surge 31% Following GPO Agreements
- Significant Stock Surge: Scienture Holdings, Inc. (SCNX) shares have risen approximately 31% in Wednesday morning trading, currently priced at $0.51, reflecting strong market response despite a slight decline from the opening price of $0.61.
- Impact of Agreements: The company has formalized multiple commercial Group Purchasing Organization agreements for its REZENOPYTM (naloxone HCl) Nasal Spray 10 mg, which is expected to significantly expand its market reach within healthcare institutions.
- Market Penetration Potential: These agreements will provide access to over 5,000 healthcare facilities, representing a potential penetration of approximately 60% of the U.S. institutional market, thereby offering robust support for future sales growth.
- Historical Trading Range: Over the past year, SCNX has traded between $0.37 and $3.17, and the current stock performance indicates a positive market sentiment regarding the company's future prospects.
See More
SCIENTURE STOCK RISES 60.1% IN PREMARKET TRADING FOLLOWING DEALS TO BROADEN DISTRIBUTION OF OPIOID OVERDOSE SPRAY
Market Growth: Shares of Scienture have increased by 60.1% in pre-market trading.
Expansion Plans: The company has signed deals to expand the reach of its opioid overdose spray.
See More
Scienture Launches ARBLI™ and Confirms REZENOPY™ Launch Timeline
- Market Opportunity Expansion: Scienture has significantly enhanced ARBLI™'s coverage in the U.S. market through agreements with multiple pharmacy benefit managers (PBMs), which is expected to drive sales growth in the $241 million losartan market, further solidifying the company's position in hypertension treatment.
- Institutional Collaboration Enhancement: The company has signed agreements with over 2,500 healthcare institutions, ensuring widespread accessibility of ARBLI™, which not only improves patient medication convenience but also lays a solid foundation for future revenue growth.
- Financial Position Improvement: As of December 31, 2025, Scienture reported approximately $7 million in cash reserves and significantly improved its balance sheet by reducing debt, providing ample funding to execute its commercial strategy and support the continued growth of ARBLI™.
- REZENOPY™ Launch Plan: Scienture has confirmed the launch of REZENOPY™ in the second quarter of 2026, marking the company's second naloxone product in the U.S. market, which is expected to leverage the commercial infrastructure established through ARBLI™ to further expand market share.
See More
